You are here: Industry Insights > Genentech

News List

Genentech buys NASH biotech Jecure pharmaphorum
November 30, 2018
Roche’s Genentech unit has bought California biotech Jecure Therapeutics, which is researching drugs that could be used in inflammatory diseases including the fatty liver disease NASH.
Roche's Genentech to acquire inflammatory drug discovery firm Jecure pharmafile
November 30, 2018
Roche’s subsidiary Genentech has finalised a definitive agreement to acquire Jecure, a US-based biotech which focuses on the discovery of drugs to treat serious inflammatory conditions, in a bid to square up to rivals in the treatment of fatty liver disea
Roche's Genentech to acquire inflammatory drug discovery firm Jecure pharmafile
November 29, 2018
Roche’s subsidiary Genentech has finalised a definitive agreement to acquire Jecure, a US-based biotech which focuses on the discovery of drugs to treat serious inflammatory conditions...
Genentech Acquires Jecure Therapeutics americanpharmaceuticalreview
November 29, 2018
Jecure Therapeutics announced a definitive agreement by which it will be acquired by Genentech, a member of the Roche Group. With this acquisition, Genentech will obtain full rights to Jecure’s entire preclinical portfolio of NLRP3 inhibitors......
Citing 'brazen' trade secrets theft, Genentech sues indicted ex-employees and biosim maker fiercepharma
November 11, 2018
The proprietary information “helped catapult JHL’s business trajectory," according to the lawsuit. JHL didn't immediately respond to a request for comment.
Affimed signs up to $5bn cancer therapeutics deal with Genentech pharmaceutical
August 30, 2018
German biopharmaceutical firm Affimed has signed a collaboration agreement with Roche unit Genentech to develop and commercialise immunotherapeutics targeting a variety of cancers.
Affimed lands big, backloaded immunotherapy deal with Genentech, sending its stock into overdrive fiercebiotech
August 29, 2018
Shares in Affimed were up more than 140% in premarket trading.
Xolair deemed ‘breakthrough’ therapy for food allergies pharmatimes
August 15, 2018
Roche/Novartis’ Xolair has been awarded breakthrough status in the US for treatment of severe allergic reactions after accidental exposure to foods allergens.
Genentech’s first implantable drug delivery system shows promising results in phase 2 wet AMD trial fiercebiotech
July 31, 2018
Genentech’s investigational, refillable eye implant—designed to deliver a new formulation of Lucentis' active ingredient, ranibizumab, continuously to wet age-related macular degeneration patients—showed positive results in a phase 2 trial compared to the
Roche’s Venclexta filed in the US for acute myeloid leukemia pharmatimes
July 13, 2018
Roche group Genentech has filed an application to market Venclexta in the US for acute myeloid leukemia (AML).

Previous page 1 2 3 4 5 6 7 8 Next page